Clinical journal of oncology nursing · 2025
Using Electronic Patient-Reported Outcome Measures for Patients With Metastatic Renal Cell Carcinoma: A Narrative Review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Minot Lucie, Javaugue Vincent, Arbutina Marlène, Emambux Sheik
Аннотация
BACKGROUND: The variety of therapeutic associations in first-line treatment of advanced and metastatic renal cell cancer (mRCC) illustrates the complexity of toxicity management that can affect patients' health-related quality of life (HRQOL). Electronic monitoring applications have become part of the daily practice of providers in following up with people with cancer.
OBJECTIVES: This article offers perspectives for electronic patient-reported outcome measures (ePROMs) in clinical practice to enhance symptom management and HRQOL for patients with mRCC.
METHODS: A narrative review combines the results of searches conducted on MEDLINE®, Embase®, and Cochrane Library for articles that identify therapeutic combinations used in treating mRCC, extract HRQOL data, and evaluate the benefits of ePROMs.
FINDINGS: ePROMs can be adapted to the toxicity and symptom specificities encountered in patients with mRCC undergoing front-line treatment. Combined with multidimensional HRQOL indicators, these tools can improve symptom management and provide early support adapted to the patient's needs.
OBJECTIVES: This article offers perspectives for electronic patient-reported outcome measures (ePROMs) in clinical practice to enhance symptom management and HRQOL for patients with mRCC.
METHODS: A narrative review combines the results of searches conducted on MEDLINE®, Embase®, and Cochrane Library for articles that identify therapeutic combinations used in treating mRCC, extract HRQOL data, and evaluate the benefits of ePROMs.
FINDINGS: ePROMs can be adapted to the toxicity and symptom specificities encountered in patients with mRCC undergoing front-line treatment. Combined with multidimensional HRQOL indicators, these tools can improve symptom management and provide early support adapted to the patient's needs.